Pancreatic cancer
Conditions
Interventions
None listed
Sponsors
Yokohama City University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with pancreatic disease (inflammation, benign or malignant) who are admitted to Yokohama City University Hospital within the study period and judged to be suitable for this study. 2. Patients planed to undergo surgery (including trial laparotomy) or chemo (radiation) therapy as initial treatments (including patients who do not require therapeutic intervention for inflammatory and benign diseases). 3. Written informed consent. 4. Age over 20.
Exclusion criteria
Exclusion criteria: 1.Patients with simultaneous or metachronous double cancer. 2.Samples taken from patients who is considered inappropriate for the inclusion by the responsible physician of each institution. 3. Patients who are pregnant or may be pregnant at the time of blood collection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the clinical diagnostic performance of TFPI2 in patients with pancreatic cancer (diagnostic accuracy, sensitivity, sensitivity, ROC curve analysis, area under the ROC curve) | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the complementarity between TFPI2 and conventional markers (CEA, CA19-9, DUPAN-2, SPAN-1). To investigate relation between TFPI2 and thrombosis (D-dimer or imge findings). | — |
Countries
Japan
Contacts
Public ContactYasuhiro Shimizu
Yokohama City University Graduate School of Medicine Department of Gastroenterological Surgery
Outcome results
None listed